Revolution Medicines Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Revolution Medicines Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10982
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Revolution Medicines Inc (Revolution Medicines) is a drug development company that discovers and develops new medicines and therapies for cancer patients. The company’s programs include SHP2 Program, 4EBP1 Program and mTORC1 Program. It develops REVBLOCKS platform, an integrated suite of modular synthesis methodologies which facilitates the production of a pipeline of drug candidates with properties based on the complex structures found in natural products. The company, through its Reveal platform, exposes advantageous structural and functional properties of scaffolds and ligands. Revolution Medicines also develops small molecule inhibitors of protein tyrosine phosphates and bRo5 small molecule drug candidates. The company partners with pharmaceutical companies and healthcare organizations for its drug development activities. Revolution Medicines is headquartered in Redwood City, California, the US.

Revolution Medicines Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Revolution Medicines Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Revolution Medicines Raises USD56 Million in Series B Financing 10
Revolution Medicines Raises Additional USD25 Million in Series A Financing 12
Revolution Medicines Raises USD45 Million in Series A Financing 13
Licensing Agreements 14
Sanofi Enters into Licensing Agreement with Revolution Medicines 14
Revolution Medicines Enters into Licensing Agreement with University of Illinois 15
Acquisition 16
Revolution Medicines to Acquire Warp Drive Bio 16
Revolution Medicines Inc – Key Competitors 17
Revolution Medicines Inc – Key Employees 18
Revolution Medicines Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Oct 05, 2017: REVOLUTION Medicines Appoints Vincent Miller, M.D. to Board of Directors 20
Mar 20, 2017: REVOLUTION Medicines Appoints Cancer Leader Dr. Stephen Kelsey as President of Research and Development 21
Product News 22
09/14/2017: Revolution Medicines reports discovery that may expand range of clinically actionable cancer mutations 22
Clinical Trials 23
Oct 11, 2018: REVOLUTION Medicines doses first patient in Phase l trial of RMC-4630 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Key Facts 2
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Revolution Medicines Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Revolution Medicines Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Revolution Medicines Raises USD56 Million in Series B Financing 10
Revolution Medicines Raises Additional USD25 Million in Series A Financing 12
Revolution Medicines Raises USD45 Million in Series A Financing 13
Sanofi Enters into Licensing Agreement with Revolution Medicines 14
Revolution Medicines Enters into Licensing Agreement with University of Illinois 15
Revolution Medicines to Acquire Warp Drive Bio 16
Revolution Medicines Inc, Key Competitors 17
Revolution Medicines Inc, Key Employees 18

List of Figures
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Revolution Medicines Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Revolution Medicines Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aksigorta A.S. (AKGRT):企業の財務・戦略的SWOT分析
    Aksigorta A.S. (AKGRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Starkey Hearing Technologies Inc:企業の戦略的SWOT分析
    Starkey Hearing Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Crescendo Bioscience Inc-医療機器分野:企業M&A・提携分析
    Summary Crescendo Bioscience Inc (Crescendo), a subsidiary of Myriad Genetics Inc is a molecular diagnostics company that concentrates on rheumatology. The company develops quantitative, objective, and biology based tests for rheumatologists. Its vectra DA is an advanced blood test for rheumatoid ar …
  • The Co-Operators Group Limited:企業の戦略的SWOT分析
    The Co-Operators Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Premera Blue Cross:企業の戦略的SWOT分析
    Premera Blue Cross - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Ichibanya Co Ltd:企業の戦略・SWOT・財務分析
    Ichibanya Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ichibanya Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Logitech International S.A.:企業の戦略・SWOT・財務分析
    Logitech International S.A. - Strategy, SWOT and Corporate Finance Report Summary Logitech International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Norish plc:企業の戦略・SWOT・財務情報
    Norish plc - Strategy, SWOT and Corporate Finance Report Summary Norish plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Intrexon Corp (XON):製薬・医療:M&Aディール及び事業提携情報
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural bio …
  • Foundation Radiology Group PC:医療機器:M&Aディール及び事業提携情報
    Summary Foundation Radiology Group PC (FRG) is a provider of radiology solutions. The company offers radiological services in areas of pediatric, neurology, mammography, musculoskeletal, PET and CT, cardiac CT and interventional radiology. It offers imaging solutions for the radiologists and systems …
  • Westport Fuel Systems Inc.:企業のM&A・事業提携・投資動向
    Westport Fuel Systems Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Westport Fuel Systems Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Snam SpA (SRG):石油・ガス:M&Aディール及び事業提携情報
    Summary Snam SpA (Snam) is an integrated midstream energy company. The company, through its subsidiaries, carries out the regasification, transportation, storage and supply of natural gas. It transports and dispatches natural gas through a transportation network, a dispatch center, supervisory distr …
  • Atrion Corp (ATRI):企業の財務・戦略的SWOT分析
    Atrion Corp (ATRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • DSK Bank EAD :企業の戦略・SWOT・財務情報
    DSK Bank EAD - Strategy, SWOT and Corporate Finance Report Summary DSK Bank EAD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Maruha Nichiro Corporation
    Maruha Nichiro Corporation - Strategy, SWOT and Corporate Finance Report Summary Maruha Nichiro Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • China Evergrande Group:企業のM&A・事業提携・投資動向
    China Evergrande Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Evergrande Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • TeleTech Holdings, Inc. (TTEC):企業の財務・戦略的SWOT分析
    TeleTech Holdings, Inc. (TTEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Petrogrand AB:石油・ガス:M&Aディール及び事業提携情報
    Summary Petrogrand AB (Petrogrand), formerly Malka Oil AB is an oil and gas company that acquires, explores and produces crude oil and natural gas assets. The company carries out management and refining of Russian oil assets. It holds interests in the Nizhne-Paninsky license area located in northwes …
  • Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆